EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.288
https://www.valueinhealthjournal.com/article/S1098-3015(23)03418-6/fulltext
Title :
EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03418-6&doi=10.1016/j.jval.2023.09.288
First page :
Section Title :
Open access? :
No
Section Order :
12133